BNRNasdaqServices-Medical Laboratories

Burning Rock Biotech Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026

$12.29−0.61 (-4.73%)

Close on Oct 19, 2026

Burning Rock Biotech Ltd income statement

AnnualQuarterlyTTM

CNY USD

Millions of CNY, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	540	516	537	563	508	430	382	209
Cost of Revenue	137	153	174	183	144	116	108	74
Gross Profit	403	362	363	380	364	314	273	135
Research & Development	166	232	347	422	368	264	157	105
Selling, General & Admin	291	453	686	939	793	462	285	191
Selling & Marketing	165	191	248	370	303	169	153	103
General & Administrative	126	262	438	568	490	294	132	88
Operating Income	-55	-358	-669	-980	-797	-412	-169	-161
Interest Expense	–	–	–	–	1.54	0.67	8.99	18
Income from Equity Investments	0	-0.09	-0.36	-0.29	-0.48	-0.28	-0.23	-0.42
Asset Impairment Charges	–	–	0	0	0	0	0	0
Gain (Loss) on Investments	–	5.32	0.22	0.11	–	–	–	–
Gain (Loss) on Sale of Assets	0.20	-2.20	-1.01	-1.42	-0.18	-0.22	-0.18	-0.04
Pretax Income	-54	-341	-651	-969	-796	-407	-169	-177
Income Tax Expense	1.56	5.89	2.39	1.99	0.90	0	0	0
Net Income incl. Noncontrolling Interests	-55	-347	-654	-971	-797	-407	-169	-177
Net Income	-55	-347	-654	-971	-797	-407	-169	-177
Net Income to Common	–	–	–	-971	-797	-472	-334	-232
EPS (Basic)(per share)	–	–	–	–	0.00	0.00	-14.23	-10.38
EPS (Diluted)(per share)	–	–	–	–	0.00	0.00	-14.23	-10.38
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	0	0	23	22
Shares Outstanding (Diluted, Weighted)(shares)	–	–	–	–	0	0	23	22
EBITDA	-33	-305	-536	-856	-749	-379	-138	-137
Total Interest Income	8.05	12	18	9.36	3.46	6.07	11	1.34
Net Interest Income	-0.03	0	0	0.10	-1.54	-0.67	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 74.7%
Operating margin: -10.2%
Net margin: -10.3%
Return on equity, FY2025: -9.9%

Financial strength

Current ratio: 2.99
Debt to equity: 0.00
Debt to assets: 0.2%
Cash to current liabilities: 193.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.